168 NOTES TO THE COMPANY FINANCIAL STATEMENTS 1 FIxEd ASSET INvESTmENTS Investments in subsidiaries Shares Total restated Loans restated $m $m $m Cost and net book value at 1 January 2008, as previously reported 15,286 15,069 30,355 Prior year adjustment UITF 44 724 724 Restated at beginning of year 16,010 15,069 31,079 Additions 14,700 787 15,487 Disposals 14,700 14,700 Transfer to current assets 2,045 2,045 Capital contribution UITF 44 178 178 Exchange 372 372 Amortisation 8 8 Repayment of loan 2,908 2,908 Cost and net book value at 31 December 2008 16,188 10,539 26,727 During 2007, the Company formed a new subsidiary, AstraZeneca Intermediate Holdings Limited.
On 11 March 2008, the Company sold its wholly owned subsidiary, AstraZeneca UK Limited, to AstraZeneca Intermediate Holdings Limited, in consideration for the issue of further shares in AstraZeneca Intermediate Holdings Limited.
During the year, the Company has adopted the requirements of UITF Abstract 44 Group and Treasury Share Transactions and restated prior year comparatives.
2 NoN-TRAdE CREdIToRS 2008 2007 $m $m Amounts due within one year Short-term borrowings unsecured 173 4,123 Other creditors 228 206 Amounts owed to group undertakings 13 24 414 4,353 3 loANS Repayment 2008 2007 dates $m $m Amounts due within one year Interest bearing loans and borrowings unsecured US dollars Floating Rate Note 2009 650 Amounts due after more than one year Amounts owed to subsidiaries unsecured US dollars 7.2% Loan 2023 283 283 Interest bearing loans and borrowings unsecured US dollars Floating Rate Note 2009 649 5.4% Callable bond 2012 1,742 1,741 5.4% Callable bond 2014 748 747 5.9% Callable bond 2017 1,742 1,741 6.45% Callable bond 2037 2,716 2,715 Euros 4.625% Non-callable bond 2010 1,053 1,099 5.625% Non-callable bond 2010 702 5.125% Non-callable bond 2015 1,051 1,099 Pounds sterling 5.75% Non-callable bond 2031 501 691 10,255 10,482 ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
